Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas.
Meningiomas are the most common canine intracranial tumour. Neurologic disability and death from treatment failure remain problematic despite current surgical and radiotherapeutic treatments for canine intracranial meningiomas. Cyclooxygenase-2 (COX-2) over-expression has been demonstrated in multiple canine malignancies, and COX-2 inhibitory treatment strategies have been shown to have both preventative and therapeutic effects in spontaneous and experimental models of cancer. The purpose of this study was to evaluate COX-2 expression in canine intracranial meningiomas. Immunohistochemical and Western blot (WB) analyses showed COX-2 expression in multiple tissues of the normal canine brain, and 87% (21/24) of intracranial meningiomas studied were immunoreactive to COX-2. No significant associations between COX-2 immunoreactivity and tumour grade were identified. Further studies are required to elucidate the physiologic roles of constitutive COX-2 expression in the central nervous system as well as its participation in meningioma tumourigenesis.
Rossmeisl
J H
JH
Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA. jrossmei@vt.edu
Robertson
J L
JL
Zimmerman
K L
KL
Higgins
M A
MA
Geiger
D A
DA
D000818:Animals; D001932:Brain Neoplasms / Q000378:metabolism / Q000662:veterinary*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D004283:Dog Diseases / Q000378:metabolism*; D004285:Dogs; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D008579:Meningioma / Q000378:metabolism / Q000662:veterinary*
D051546:Cyclooxygenase 2